Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Dimethyl Sulfoxide→

Dimethyl Sulfoxide Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
67-68-5
Molecular formula
C2H6OS
Molecular weight
78.133 g/mol
Drug class
Polar aprotic solventtopical and intravesical medicinal agent with anti-inflammatory/analgesic properties
Mechanism of action
Has solvent and membrane-penetration properties and can modulate inflammatory and nociceptive pathways; the mechanism underlying clinical benefit in interstitial cystitis is not fully understood.
Indications / reported uses
  • Intravesical treatment of interstitial cystitis/bladder pain syndrome in adults using the authorised 50% DMSO bladder instillation product; other topical or industrial uses are not equivalent to this medicinal indication

Sources: US DailyMed — RIMSO-50 (dimethyl sulfoxide) · US FDA prescribing information · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Polar aprotic solvent; topical and intravesical medicinal agent with anti-inflammatory/analgesic properties

Mechanism of action

Has solvent and membrane-penetration properties and can modulate inflammatory and nociceptive pathways; the mechanism underlying clinical benefit in interstitial cystitis is not fully understood.

General use cases

  • Intravesical treatment of interstitial cystitis/bladder pain syndrome in adults using the authorised 50% DMSO bladder instillation product; other topical or industrial uses are not equivalent to this medicinal indication

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Dimethyl Sulfoxide Environmental Risk Assessment (ERA) (the Dimethyl Sulfoxide ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.